There is growing interest in mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) as key components in the development of next-generation…

What peer-reviewed studies show about human platelet lysate vs FBS and serum-free media for MSC expansion, with an evidence table by cell type and FAQ.

Implements Metric-T, a permutation-based diagnostic that flags when the reported direction of a group difference in electroencephalography (EEG) functional connectivity depends on the choice of metric. Direction consistency (DC) converts the weighted phase lag index (wPLI) and magnitude-squared coherence (MSC), both derived from the same cross-spectrum, into the percentage of channel-pair features for which one group exceeds the other; Metric-T is T = DC(wPLI) - DC(MSC). Significance is assessed by aligned label permutation with marginal and Westfall-Young max-T multiplicity control. For small samples the reference set is enumerated completely: exact two-group tests, the complete two-group labelling space (in which cut-points, exclusions and batches are located on one distribution), and a stratified exact test for a continuous covariate. Core functions use base R only; a 'shiny' graphical interface is included. Method: Kimura (2026) &lt;<a href="https://doi.org/10.1016%2Fj.neuri.2026.100286" target="_top">doi:10.1016/j.neuri.2026.100286</a>&gt;.

Implements Metric-T, a permutation-based diagnostic that flags when the reported direction of a group difference in electroencephalography (EEG) functional connectivity depends on the choice of metric. Direction consistency (DC) converts the weighted phase lag index (wPLI) and magnitude-squared coherence (MSC), both derived from the same cross-spectrum, into the percentage of channel-pair features for which one group exceeds the other; Metric-T is T = DC(wPLI) - DC(MSC). Significance is assessed by aligned label permutation with marginal and Westfall-Young max-T multiplicity control. For small samples the reference set is enumerated completely: exact two-group tests, the complete two-group labelling space (in which cut-points, exclusions and batches are located on one distribution), and a stratified exact test for a continuous covariate. Core functions use base R only; a 'shiny' graphical interface is included. Method: Kimura (2026) &lt;<a href="https://doi.org/10.1016%2Fj.neuri.2026.100286" target="_top">doi:10.1016/j.neuri.2026.100286</a>&gt;.

Background Current barriers to achieving radical life extension include the inability to use syngeneic, youthful mesenchymal stem cells (MSCs) and the anti-regenerative effects of senescence-associated secretory phenotype (SASP) factors. We aim to overcome this by a combination approach in which senescent cell burden is reduced utilizing SenoVax™ a dendritic cell based senolytic immunotherapy combined with syngeneic pluripotent stem cell derived MSC. Methods We induced hepatic injury and accelerated aging using two established murine models: carbon tetrachloride (CCl₄) mediated liver injury and doxorubicin induced systemic senescence. Animals were treated with control, SenoVax, pMSCs or the combination. Outcomes included biochemical and histologic indices of liver injury, circulating and tissue biomarkers of senescence (IL-11, YKL-40, IL-6, IL-23 R) and regeneration (Klotho, FGF-2, neo-VEGF, GDF-11), Results Both CCl₄ and doxorubicin induced a robust senescent phenotype characterized by increased pro-inflammatory and pro-fibrotic mediators and downregulation of regenerative biomarkers. Combined senolytic and pMSC therapy outperformed mono therapies and produced clear synergistic benefits, including significant biochemical improvement of liver failure parameters, reversal of accelerated aging features, and restoration of regenerative signaling pathways. Senolytic monotherapy yielded partial improvements, while pMSCs alone showed limited activity in the presence of a high senescent-cell burden. Conclusions These findings support a mechanistic model in which senescent cells and SASP factors directly suppress MSC-mediated tissue repair. Targeted senolytic immunotherapy enhances the efficacy of regenerative interventions and represents a promising combinatorial strategy for chronic disease management and potentially for modifying biological aging itself. Clinical trial number Not applicable.

We decompose Antarctic sea ice volume (SIV) into dynamic and thermodynamic terms over 2014–2020, using a novel year-round, dual-frequency sea ice thickness product Winter SIV is largely determine...

Background Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder and disproportionately affects women, with neuroinflammation emerging as a key driver of disease onset and progression. Beyond amyloid-β (Aβ) and hyperphosphorylated tau protein accumulation, chronic activation of microglia and astrocytes amplifies synaptic dysfunction and neuronal loss. Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) represent a promising translational strategy due to their capacity to modulate inflammation and promote neuroprotection. Here, we investigated whether intranasal administration of extracellular vesicles derived from human amniotic membrane MSCs (hAMSC-EVs) could counteract cognitive decline, neuroinflammation, and synaptic alterations in experimental and human cellular models of AD. Methods hAMSC-EVs were isolated and characterized for size, markers, and biodistribution. Female 3 × Tg-AD mice received chronic intranasal hAMSC-EV administration from 3 to 9 months of age. Cognitive performance was assessed using novel object recognition, object place recognition, and Y-maze tests. Hippocampal Aβ levels, tau phosphorylation, glial density, microglial morphology, cytokine profiles, and synaptic protein expression were analyzed by immunoblotting, ELISA, immunofluorescence, and morphometric analyses. Bioinformatic analyses were performed to investigate the miRNA cargoes of hAMSC-EVs. Translational relevance of the hAMSC-EV effects was assessed in glutamatergic neurons differentiated from induced pluripotent stem cells derived from sporadic AD patients. Results The hAMSC-EVs delivered intranasally reached the hippocampus and were internalized by neurons and microglia. hAMSC-EV treatment significantly improved cognitive performance of female 3 × Tg-AD mice and reduced hippocampal Aβ levels without affecting tau phosphorylation. The hAMSC-EVs attenuated neuroinflammation by reducing microglial and astrocytic density, inducing microglial structural remodeling, and downregulating TMEM119 and TREM2 expression. We also detected a shift toward an anti-inflammatory cytokine profile and increased expression of neuroplasticity-related proteins, including BDNF, GluA1, and ARC in the hippocampus of 3 × Tg-AD mice. Bioinformatic analyses identified EV miRNA cargoes enriched in immunomodulatory and neuroprotective pathways. In human AD neurons, hAMSC-EVs prevented neurite atrophy and rescued synaptic protein expression without affecting the cell viability. Conclusions hAMSC-EVs exert robust anti-inflammatory and neuroprotective effects in both murine and human AD models, improving cognition, modulating glial activation, and restoring synaptic integrity. These findings highlight the translational potential of intranasal hAMSC-EVs as an adjuvant therapeutic strategy targeting neuroinflammation and neurodegeneration in AD.

Mesenchymal stem/stromal cell (MSC)-based therapy holds promise for reversal of bone loss in osteoporosis. This phase 1 study establishes the safety and feasibility of intravenous administration of glycocalyx-engineered human MSCs and provides evidence that MSCs derived from the bone marrow of older individuals with osteoporosis retain clinically meaningful osteoregenerative capacity.

The field of regenerative medicine is gaining momentum. Mesenchymal stem cells (MSCs) remain central to this field, with expanding applications as direct therapies and as producers of MSC-derived extracellular vesicles (MSC-EVs). This article examines the biological and regulatory factors shaping their promise. The post Regenerative Medicine in the Bronze Age: MSCs and MSC-EVs Leading the Way appeared first on GEN - Genetic Engineering and Biotechnology News .

Read the full paper: Fuzheng Buxue Dietary Therapy-Preconditioned MSC-Derived Extracellular Vesicles Promote Hematopoietic Recovery in Chemotherapy-Induced Myelosuppression